NCT06315283View on ClinicalTrials.gov

An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

March 20, 2024

Primary Completion Date

August 14, 2025

Study Completion Date

September 4, 2025

Conditions
Schizophrenia
Interventions
DRUG

TV-44749

Administered subcutaneously (sc)

DRUG

Oral olanzapine

Administered orally

Trial Locations (9)

10090

Teva Investigational Site 60053, Zagreb

30030

Teva Investigational Site 15742, Decatur

30331

Teva Investigational Site 15741, Atlanta

33024

Teva Investigational Site 15738, Hollywood

49021

Teva Investigational Site 31326, Zamora

90504

Teva Investigational Site 15740, Torrance

90720

Teva Investigational Site 15739, Los Alamitos

08053

Teva Investigational Site 15737, Marlton

KT22 7AD

Teva Investigational Site 34310, Surrey

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D LLC

INDUSTRY

NCT06315283 - An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia | Biotech Hunter | Biotech Hunter